Clinical trials: Nonalcoholic Steatohepatitis
Nonalcoholic Fatty Liver, Weight Loss
Study on GS300 on NAFLD
To determine the efficacy of GS300 when administered for 24 weeks in patients with Nonalcoholic Fatty Liver Disease (NAFLD).
- Trial name
- REVERT (NCT04887766)
- Testing
- GS300
- Volunteers
- 250 people
- Sponsor
- Gelesis, Inc.
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Nonalcoholic Fatty Liver Disease
The objective is to evaluate the efficacy and safety of once-daily oral doses of 10 mg elobixibat in combination with 9g cholestyramine powder (cholestyramine 4g) in patients with nonalcoholic fatty liver disease (NAFLD) or…
- Trial name
- NCT04235205
- Testing
- Elobixibat 10mg + cholestyramine powder 9g (cholestyramine 4g)
- Where
- Japan
- Volunteers
- 102 people
- Sponsor
- Yokohama City University
Cardiovascular Diseases
Molecular Investigation of Genetic Factors in CArDiovascular Diseases Using an BIOresource of Healthy Volunteers
The risk of cardiovascular disease is determined by the complex interplay between an individual's genetic make-up, lifestyle, and the environment.
- Trial name
- CADBIO (NCT03038750)
- Testing
- Eligibility and lifestyle restrictions check., Medical history, demographic and lifestyle factors, Anthropometric measurements: height, weight, and body fat
- Where
- United Kingdom
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Metabolic Dysfunction-associated Fatty Liver Disease
Efficacy and Safety of Calculus Bovis Sativus in Adults With MAFLD
Metabolic dysfunction-associated fatty liver disease (MAFLD) has become the most common chronic liver disease worldwide. Timely therapeutic intervention for MAFLD is crucial for improving patient prognosis and preventing its…
- Trial name
- NCT07085962
- Testing
- Calculus bovis sativus
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Huazhong University of Science and Technology
Nonalcoholic Fatty Liver Disease, Type 2 Diabetes
Weight Gain After Smoking Cessation and NAFLD
Nonalcoholic fatty liver disease (NAFLD) is rapidly becoming the most common chronic liver disease. Considering that there are no approved pharmacological treatments, lifestyle modification is necessary and challenging to reduce…
- Trial name
- NCT05550688
- Where
- China
- Volunteers
- 12,941 people, healthy volunteers welcome
- Sponsor
- Ningbo No. 1 Hospital
Fatty Liver, Nonalcoholic
Probiotic Supplement Versus Placebo for the Treatment of Patients With Non-alcoholic Fatty Liver Disease
Probiotic supplement versus placebo for the treatment of patients with non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial
- Trial name
- NCT06491342
- Testing
- Probiotic
- Where
- 2 sites in Thailand
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Phramongkutklao College of Medicine and Hospital
Diabetes Mellitus, Type 2, NASH - Nonalcoholic Steatohepatitis
Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver
This randomized clinical trial aims to compare the effect of the pioglitazone and SGLT2 inhibitor combination on liver fat mass, as compared to either drug used alone, with or without background medical therapy of metformin…
- Conditions
- Diabetes Mellitus, Type 2, NASH - Nonalcoholic Steatohepatitis, NAFLD
- Trial name
- NCT04976283
- Testing
- Pioglitazone, Empagliflozin, Pioglitazone + Empagliflozin
- Where
- Pakistan
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- Getz Pharma
NASH - Nonalcoholic Steatohepatitis, Cirrhosis
Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-14
To validate the ability of the Methacetin Breath Test (MBT) to detect clinically significant portal hypertension (CSPH)/severe portal hypertension (SPH) defined as hepatic venous pressure gradient (HVPG) ≥ 10 mmHg and HVPG ≥ 12…
- Conditions
- NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Portal Hypertension
- Trial name
- NCT03439189
- Testing
- Methacetin Breath Test, Emricasan
- Where
- France
- Volunteers
- 343 people
- Sponsor
- Meridian Bioscience, Inc.
Non-Alcoholic Fatty Liver Disease
Effectiveness and Adherence of Modified Alternate-day Calorie Restriction (MACR) in Non-Alcoholic Fatty Liver Disease
There is no effective therapy for non-alcoholic fatty liver disease (NAFLD), although intensive calorie restriction is typically recommended but dietary adherence is an issue.
- Trial name
- NCT03791203
- Testing
- Calorie restriction (MACR)
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Universiti Sains Malaysia
Non-Alcoholic Fatty Liver Disease
The Nijmegen-Leiden-Amsterdam 2-tiered Care Path Study
Non-alcoholic fatty liver disease (NAFLD) is a liver disease, caused by storage of fat in the liver. The most-important risk-factors are being overweight, and disorders in sugar and cholesterol handling of the body.
- Trial name
- NLA2 (NCT05712603)
- Testing
- FIB4-score, Vibration controlled transient elastography, Enhanced Liver Fibrosis test
- Where
- 3 sites in Netherlands
- Volunteers
- 655 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Non-alcoholic Fatty Liver Disease
Runihol in Nonalcoholic Fatty Liver Disease and Metabolic Syndrome
The study is designed to assess the safety and efficacy of different doses and dosing regimens of Runihol, tablets, enteric coated, produced by "NTFF" POLYSAN" (Russia), in prevention of liver disease progression in patients with…
- Trial name
- NCT02930161
- Testing
- Runihol
- Where
- 3 sites in Russia
- Volunteers
- 35 people
- Sponsor
- POLYSAN Scientific & Technological Pharmaceutical Company
NASH - Nonalcoholic Steatohepatitis
Multiple Ascending Dose Study of HU6 in High BMI Volunteers
This is a 14-day multiple ascending dose trial in high BMI volunteers in up to 4 cohorts of 10 high BMI volunteers each consisting of 8 receiving HU6 and 2 receiving placebo.
- Trial name
- NCT04709913
- Testing
- HU6
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Rivus Pharmaceuticals, Inc.
Healthy Volunteers, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
This study is researching an experimental drug called ALN-PNP (called "study drug"). This is a first in human study. The study drug is not approved by any public health agency such as the United States Food and Drug…
- Trial name
- NCT05648214
- Testing
- ALN-PNP
- Where
- 6 sites in United States
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Non Alcoholic Steatohepatitis
the Efficacy and Safety of Diosmin on Non-diabetic Patients With Non-alcoholic Steatohepatitis.
This is a randomized, controlled study evaluating diosmin tablets administered daily for 3 months. The purpose of the study is to evaluate the efficacy and safety of diosmin on non-diabetic patients with non-alcoholic…
- Trial name
- NCT05942547
- Testing
- Diosmin
- Where
- Egypt
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Tanta University
Chronic Hepatitis b, Non-alcoholic Fatty Liver Disease
Risk Factors for Hepatic Inflammation, Fibrosis and Prognosis in Patients With CHB and NAFLD
Chronic hepatitis B (CHB) affects an estimated 292 million people, and causes approximately 800,000 people deaths per year from liver-related complications including cirrhosis and hepatocellular carcinoma, remaining a major…
- Trial name
- NCT05766449
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Non-Alcoholic Fatty Liver Disease, Liver Disease; Alcohol-Related
FibroScan-Reproducibility and Repeatability Study
Chronic liver disease (CLD) is a serious health issue worldwide, often progressing without symptoms until advanced stages with risks of complications like liver cancer and cirrhosis.
- Trial name
- FibroScan-RR (NCT06877026)
- Testing
- FibroScan, Liver Enzymes
- Where
- United Kingdom
- Volunteers
- 108 people
- Sponsor
- Echosens
Nonalcoholic Fatty Liver Disease, HIV
Aramchol for HIV-associated Nonalcoholic Fatty Liver Disease and Lipodystrophy
A subset of patients with NAFLD that have not been extensively studied are those infected with human immunodeficiency virus (HIV). Currently, there is no FDA approved treatment for NAFLD or NASH.
- Trial name
- ARRIVE (NCT02684591)
- Testing
- Aramchol
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Diego
Fasting, Non-alcoholic Fatty Liver Disease (NAFLD)
Regulation of FGF21 by Nutritional Challenges
The purpose of this study is to examine how acute nutritional challenges affect levels of several proteins involved in metabolism. These proteins will be measured in blood and fat tissue. This study will have several aims.
- Trial name
- NCT00968747
- Testing
- Fasting, Diet, oral carbohydrate challenge
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Overweight/obesity, Metabolic Associated Fatty Liver Disease
Effect of Low Valine Diet on Body Weight and Metabolic Parameters
This study aimed to explore the effects of ordinary meal replacements and low-valine meal replacements on the weight and risk of related metabolic diseases in overweight/obese patients through a randomized double-blind controlled…
- Conditions
- Overweight/obesity, Metabolic Associated Fatty Liver Disease, Metabolic Diseases
- Trial name
- NCT06883578
- Testing
- Short-term continuous normal meal replacement, Short-term continuous low-valine meal replacements, Long-term intermittent normal meal replacement
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Shanghai Zhongshan Hospital
Impaired Glucose Tolerance, Pre-diabetes
Study to Investigate the Pathophysiology of Type 2 Diabetes in Youth
The purpose of the study is to determine the role of beta-cell function and insulin resistance in the development of impaired glucose tolerance (IGT) and type 2 diabetes in children and adolescents who have an increased risk of…
- Conditions
- Impaired Glucose Tolerance, Pre-diabetes, Childhood Obesity, Insulin Resistance
- Trial name
- NCT00536250
- Where
- United States
- Volunteers
- 255 people, healthy volunteers welcome
- Sponsor
- Yale University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.